IBM Ventures participated in a $20m round for the neurological disease diagnostics technology developer, a spinout from Tel Aviv University.

Variantyx, a US-based developer of hereditary disease testing technology, received $20m yesterday in a series C round featuring IBM Ventures, the corporate venturing subsidiary of computing technology producer IBM.

GHS Fund, a joint venture between Quark Venture and GF Securities, led the round, which included Pitango Venture Capital, New Era Capital Partners and 20/20 HealthCare Partners.

Founded in 2014 as a Tel Aviv University spinout, Variantyx has developed genome sequencing technology used to test for rare inherited and neurological diseases.